


Cite this: *RSC Adv.*, 2024, 14, 29395

# Total synthesis of (–)-2-oxo epimesembranol and (+)-dihydromaritidine via a key Johnson–Claisen rearrangement†

Satyajit Majumder,<sup>a</sup> Abhinay Yadav,<sup>a</sup> Souvik Pal,<sup>a</sup> Abhishek Mondal<sup>b</sup> and Alakesh Bisai<sup>\*ab</sup>

A general approach to *Sceletium* alkaloids of the family *Aizoaceae* following a key Johnson (orthoester)–Claisen rearrangement of an enantioenriched allylic alcohol has been disclosed. The tricyclic core (**1c**) of *cis*-3*a*-octahydroindoline skeleton was achieved via an ester-aminolysis followed by an intramolecular aza-Michael reaction with amine under elevated temperature. Utilizing aforementioned strategy, a collective total syntheses of *Sceletium* alkaloids, such as (–)-2-oxo-epimesembranol (**1d**) [the first total synthesis], (–)-6-epimesembranol (**1b**), and (–)-mesembrine (**1a**) were shown. Further this strategy was applied for total synthesis of (+)-dihydromaritidine (**2c**) sharing [5,11*b*]-ethanophenanthridine skeleton.

Received 20th July 2024  
Accepted 9th September 2024

DOI: 10.1039/d4ra05275g

rsc.li/rsc-advances

## Introduction

*Amaryllidaceae* alkaloids are a structurally diverse group of plant specialized metabolites with important biological activities.<sup>1</sup> Plants belonging to the *Amaryllidaceae* and *Sceletium* family are herbaceous perennials that grow from bulbs.<sup>2,3</sup> More than 500 *Amaryllidaceae* alkaloids have been isolated, with varied biological profiles, from *Amaryllidaceae* plants till date.<sup>3,4</sup> In particular, the *Sceletium tortuosum*, is an indigenous herb of South Africa, especially in Namaqualand, where the plant is utilized regularly as an herbal supplement in the treatment of central nervous system-related disorders for nearly 200 years.<sup>5,6</sup> main alkaloid responsible is mesembrine (**1a**) and mesembranol (**1b**).<sup>7,8</sup> They are also cultivated as ornamental plants for their beautiful flowers and to produce volatile oil. These alkaloids contain common core *cis*-3*a*-octahydroindoline skeleton along with a synthetically challenging benzylic all-carbon quaternary stereocenter.<sup>9</sup> Their architecture display vicinal quaternary and tertiary carbon stereocenters<sup>10</sup> with a fused pyrrolidine ring,<sup>11</sup> as common structural features, whose stereochemical incorporation is indeed a challenge. As a representative alkaloid of the *Amaryllidaceae* family with significant biological activity, maritidine<sup>12</sup> is isolated from *Pancratium maritimum*, *Pancratium tortuosum*, and *Zephyranthes* genera,<sup>13</sup> with a 5,10*b*-ethanophenanthridine nucleus containing

dimethoxy substituents at C-8 and C-9 positions. Maritidine is of particular interest due to its cytotoxic properties<sup>14,15</sup> and limited supplies from natural sources.

It is important to note that, both antipodes of *Amaryllidaceae* alkaloids are naturally occurring. As for example (–)-crinine (**2d**) and its enantiomer (+)-vittatine (*ent*-**2d**) are isolated from different *Amaryllidaceae* species.<sup>5,15</sup> Similarly, naturally occurring (–)-*epi*-crinine (**2f**) and its enantiomer (+)-*epi*-vittatine (*ent*-**2f**) are also isolated from different *Amaryllidaceae* species.<sup>5</sup>

The incorporation of sterically congested quaternary center is the critical element in the total synthesis *Amaryllidaceae* alkaloids sharing [5,10*b*]-ethanophenanthridine<sup>16</sup> and *cis*-3*a*-octahydroindoline alkaloids<sup>17,18</sup> Although great efforts have been devoted to the development of synthetic methods to obtain maritidine type alkaloids, most of the reported approaches provided racemic products,<sup>10</sup> and only a few asymmetric syntheses of maritidine have been reported.<sup>15,16</sup>

In this regard, the development of a general and efficient asymmetric catalytic method for the concise synthesis of *Amaryllidaceae* and *Sceletium* family of alkaloids having benzylic quaternary stereogenic center has become an important subject in organic chemistry. In this regard, in 2002, Trost and co-workers studied the direct intramolecular Pd(0)-catalyzed asymmetric decarboxylative allylic alkylation of enol carbonates and subsequently, allylation of 2-phenylcyclohexanone (88% ee using **L2**, 2009).<sup>19a,b</sup> However, it has been reported that the utilization of electron-rich aromatics rather very difficult. Kim *et al.*<sup>20a</sup> have reported that only 66% ee was obtained for **3a** sharing 3,4-diOMePh as an aryl group using 5.5 mol% of **L2** (Fig. 2), clearly indicating that utilization of such process with a substrate sharing electron-donating aromatic rings is indeed a considerable challenge that is worth testing. In 2018, our group also shown via an elegant Pd(0)-catalyzed Asymmetric

<sup>a</sup>Department of Chemistry, Indian Institute of Science Education and Research Bhopal, Bhauli, Bhopal-462 066, Madhya Pradesh, India. E-mail: alakeshb@gmail.com

<sup>b</sup>Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, Nadia-741 246, West Bengal, India. E-mail: alakesh@iiserkol.ac.in

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra05275g>






Fig. 1 Selected naturally occurring *Scelletium* alkaloids and *Amaryllidaceae* alkaloids.

Allylic Alkylations (AAA)<sup>20b</sup> of allyl enol carbonates (**3b** in 92% ee using **L1**) (Fig. 2). Further, Wang *et al.*<sup>20c</sup> has reported an elegant Pd(0)-catalyzed asymmetric allylation of  $\alpha$ -aryl vinyllogous ester **3c** (84% ee) using **L2** for an asymmetric total synthesis of (-)-oxomaritidine (**2b**) (Fig. 2).

It is clear from the literature that it is difficult to get high enantioselectivity of electron-rich enol carbonates *via* Pd(0)-catalyzed Asymmetric Allylic Alkylations (AAA). It is believed






Fig. 2 Catalytic enantioselective allylation.



Scheme 1 Retrosynthetic analysis.

that a substrate having catechol methyl ether might be coordinating with the Pd(0) (see a proposed complex shown in Fig. 2), thereby hampering its catalytic efficiencies in terms of chemical yield (58%) as well as optical purity (66% ee). Thus, a concise catalytic asymmetric approach to the *Amaryllidaceae* alkaloids sharing electron-rich aromatics remains a challenge that is worth pursuing. Retrosynthetically, it was hypothesized that a Johnson-Claisen rearrangement of 3-(3,4-dimethoxyphenyl)cyclohex-2-enol can be an excellent strategic platform to install the all-carbon quaternary stereocenter required for unified strategy for *Scelletium* and *Amaryllidaceae* alkaloids shown in Fig. 1. The retrosynthetic analysis of the asymmetric total synthesis of *cis*-3a-octahydroindoline alkaloids is shown in Scheme 1. For a unified approach to the *Scelletium* alkaloids and *Amaryllidaceae* alkaloids, it was envisioned that a Johnson-Claisen rearrangement<sup>21</sup> of enantioenriched allylic alcohol **9b** followed by allylic oxidation (see **7b**)<sup>22a</sup> and ester aminolysis (see **5**) and aza-Michael reaction (**6b** and **1c**)<sup>23</sup> to address total synthesis of several congeners of these alkaloids.



Scheme 2 Synthesis of enantioenriched 3-(aryl)cyclohex-2-enols (+)-9b.


It was hypothesized that the advanced intermediate, a benzylic all-carbon quaternary stereocenter containing  $\gamma,\delta$ -unsaturated ester **8b**, could undergo direct allylic oxidation to generate the substrate for the amidation/transannular aza-conjugate addition reaction, leading to a unified pathway to access both *Sceletium* and *Amaryllidaceae* type alkaloids (Scheme 1). Enone-ester **7b** can be synthesized *via* allylic oxidation of cyclohexene **8b**, which can be obtained through the Johnson–Claisen rearrangement of allylic alcohol **9b**. At this stage, it was proposed that the enantioenriched 3-(aryl)cyclohex-2-enols **9b**, which can be accessed through the enantioselective CBS reduction of 3-aryl-2-cyclohexenone **11b** (Scheme 2), could provide a pathway to an asymmetric synthesis. Compound **11b** can be readily synthesized from vinylogous ester **10b** through a well-established Stork–Danheiser sequence.

## Results and discussion


Moving forward with above proposed strategy, it was required to synthesize enantioenriched 3-(aryl)cyclohex-2-enols **9b** for the orthoester Johnson–Claisen rearrangement (Scheme 2). Towards this, the Stork–Danheiser sequence on compound **10b** using aryl magnesium bromide was carried out to afford 3-aryl-2-cyclohexenone **11b** in 82% yields (Scheme 2). Next, it was identified that Corey–Bakshi–Shibata (CBS) reduction was reliable to reduce substituted cyclic enones in high enantioselectivity.

In this regard, we first observed that coordinating polar aprotic solvent THF may reduce the acidity of  $\text{BH}_3 \cdot \text{Me}_2\text{S}$  results it unable to complete catalytic cycle of CBS reduction even in refluxing condition. Later on, we investigated that polar aprotic noncoordinating solvent  $\text{CH}_2\text{Cl}_2$  unable to reduce acidity of  $\text{BH}_3 \cdot \text{Me}_2\text{S}$  results to complete the catalytic cycle of CBS reduction at rt with 20 mol% catalyst. (*R*)-CBS reagent was used for the optimization of enantioselective reduction of 3-aryl-2-cyclohexenone **11b**.<sup>22b</sup> However, our initial results in this direction were rather discouraging and it was found that even after using 100 mol% (*R*)-CBS reagent, a maximum of 42% ee was observed.

It was argued that a sterically crowded easily removable group might help in bringing high enantioselectivity (Scheme 3). Thus, a halogen group such as bromo group that can be easily remove *via* reductive condition was incorporated. Therefore, Stork–Danheiser sequence bromo vinylogous ester **10a** was carried out using aryl magnesium bromide to afford 2-bromo-3-aryl-2-cyclohexenone **11a** in 82% yields (Scheme 4). Luche reduction of 2-bromo enone provided racemic allyl alcohol **12a** for HPLC analysis.



Scheme 3 Retrosynthetic analysis.



Scheme 4 Synthesis of enantioenriched 3-(aryl)cyclohex-2-enols (+)-**9b**.

Next, 2-bromo-3-aryl-2-cyclohexenone **11a** in hand it was explored under Corey–Bakshi–Shibata (CBS) reduction and the result is summarized in Table 1. The optimization studies were conducted in different solvents such as THF and dichloromethane under different temperature using (*R*)-CBS reagent. The initial result using 50 mol% (*R*)-CBS afforded allyl alcohol in 90% ee (entry 3, Table 1). Following exhaustive optimization, it was observed that dichloromethane is a better solvent for this transformation and 100 mol% of (*R*)-CBS in dichloromethane at room temperature afforded allyl alcohol in 97% ee (entry 7, Table 1). Gratifyingly, using 50 mol% of (*R*)-CBS in dichloromethane furnished product in 94% ee (entry 8, Table 1). On further decrease of catalyst loading to 20 mol% of (*R*)-CBS, and

Table 1 Optimization of electron rich bromo-enone CBS reductions

Entry <sup>a</sup>	( <i>R</i> )-CBS reagent	Solvent	Temp.	Time	Yield <sup>b</sup>	% ee <sup>c</sup>
1	100 mol%	THF	0 °C	24 h	0	—
2	100 mol%	THF	25 °C	0.5 h	91%	90%
3	50 mol%	THF	25 °C	0.5 h	50%	90%
4	50 mol%	THF	60 °C	24 h	61%	81%
5	100 mol%	$\text{CH}_2\text{Cl}_2$	0 °C	24 h	10%	—
6	20 mol%	$\text{CH}_2\text{Cl}_2$	25 °C	0.5 h	98%	92%
7	100 mol%	$\text{CH}_2\text{Cl}_2$	25 °C	0.5 h	93%	97%
8	50 mol%	$\text{CH}_2\text{Cl}_2$	25 °C	2 h	92%	94%
9 <sup>d</sup>	20 mol%	$\text{CH}_2\text{Cl}_2$	25 °C	3 h	94%	99%

<sup>a</sup> All the reactions were performed under argon atmosphere. <sup>b</sup> Yields are reported after column chromatography. <sup>c</sup> ee's were measured performing HPLC analysis by Chiralpak OD-H column. <sup>d</sup> Slow addition by syringe pump over 3 h.




Fig. 3 Plausible transition states.

under slow reverse addition of bromo-enone **11a**, it was found to achieve a 99% ee (entry 9, Table 1).

The stereochemical rationale of Corey–Bakshi–Shibata (CBS) reduction of 2-bromo-3-aryl 2-cyclohexenone **11a** *via* transition state models are shown in Fig. 3.<sup>22c</sup> It is very clear that the bromide of bromo-enone is imparting enhanced facial bias of the ketone leading to increased enantioselectivities and is subsequently removed *via* a debromination step following the reduction. The asymmetric aspect of this overall transformation is therefore simplified to the preparation of an enantioenriched allylic alcohol. Thus, this account for the perfect enantioselectivity (99% ee) achieved from this reaction. In the favored transition state of CBS reduction [using (*S*)-CBS reagent] of 2-bromo-3-aryl 2-cyclohexenone **11a** one could easily account for a ‘*Si*-face’ approach of hydride *via* a six-membered cyclic transition state in achieving optimum enantioselectivity in this process (Fig. 3). It is apparent that a bulky group such as bromo has an important role in controlling enantioselectivity, which in fact helps in retarding the ‘disfavored’ transition state and, thus, avoids ‘*Re*-face’ approach of hydride onto the carbonyl group (Fig. 3, see above). The transition state for the reduction of 2-bromo-3-aryl 2-cyclohexenone **11a** using (*R*)-CBS reagent has also been shown in Fig. 3 (see above). In this case a ‘*Re*-face’ approach of hydride *via* a six-membered cyclic transition state is favored, whereas a ‘*Si*-face’ approach of hydride is retarded because of the steric clash (Fig. 3, see above).

The beauty of choosing a bromo group is two-fold in our synthesis: firstly, it helps in achieving highest enantioselectivity and, secondly, this group can easily be removed by the reaction with organometallic reagents such as by the treatment with

*n*-BuLi followed by quench by water or by a reaction with *n*-Bu<sub>3</sub>SnH in the presence of catalytic AIBN (azo-bis isobutyronitrile) or using Pd(0)-catalyzed cross-coupling with a hydride source. In particular, the bromo group of allyl alcohol was removed by using *n*-BuLi at low temperature to generate vinyl carbanion which was further reacted with water to get allyl alcohol **9b** in 98% ee (Scheme 4).

Further, orthoester Johnson–Claisen rearrangement of 3-(aryl)cyclohex-2-enols **9b** with triethyl orthoacetate was investigated in different solvent and in presence of catalytic amount of weak acid under heating condition (Table 2). Triethyl orthoacetate was activated in presence of catalytic amount of weak acid under heating condition to produce ketene-acetal intermediate which undergoes [3,3]-sigmatropic rearrangement results  $\gamma,\delta$ -unsaturated ester. Initially this reaction was performed in the presence of propanoic acid, pivalic acid, butyric acid and *o*-nitrophenol at different temperatures (Table 2). Following an exhaustive optimization, it was observed that acid catalysed orthoester Johnson–Claisen rearrangement of allyl alcohol **9b** afforded product **8b** with benzylic all-carbon quaternary stereogenic center in 62% isolated yield when 5 mol% of *o*-nitrophenol was employed as catalyst. The enantioselectivity of product **8b** found to be compromised to 68% ee from 99% ee of starting allylic alcohol (entry 6, Table 2).

In order to understand the loss of enantiopurity, it was thought of looking at the mechanism of orthoester Johnson–Claisen rearrangement (Scheme 5). Acid catalyzed activation of triethyl orthoacetate could form an oxocarbenium ion that could react with the allyl alcohol to generate the intermediate **16b** responsible for the [3,3]-sigmatropic rearrangement *via* the intermediates **16b–18b** (Scheme 5). Since the reaction goes through a concerted pathway, therefore, in principle, an enantioenriched allyl alcohol **9b** having >99% ee should provide product **8b** in >99% ee *via* an enantioenriched intermediate **18b** (>99% ee).


However, our result suggests that the electron-rich aromatics probably has a bigger role in the orthoester Johnson–Claisen rearrangement of 3-(aryl)cyclohex-2-enol **9b**. It is believed that the enantioselectivity of the enantioenriched intermediate **18b** is somehow compromising to 68% ee during the course of the reaction, and therefore, this account for the observed enantioselectivity of **8b** as 68% ee (entry 6, Table 2). A rationale of by product formation under this type of pericyclic reaction using electron-rich aromatic ring is shown in Scheme 6.

It is believed that 3-(aryl)cyclohex-2-enols **9b** could generate some amount of an allylic carbocation such as **Ab** (through the intermediate **Aa**) in the course of reaction (Scheme 6), which is getting stabilized by the electron-donating nature of aromatic ring, in particular, 4-methoxy group of aryl ring present in the 3-position of allyl alcohol (see the formation of **Ab** from **Ac**). The allylic carbocation **Ab** could recombine with ethyl orthoacetate to reform intermediate **Ac** (68% ee) responsible for the [3,3]-sigmatropic rearrangement product.

Thus, it was thought of exploring the *ortho*-ester Johnson–Claisen rearrangement of 3-(aryl)cyclohex-2-enols **9b** under basic condition (entries 7–10, Table 2). Under the thermal decomposition of triethyl orthoacetate one could able to






Table 2 Optimization of *ortho*-ester Johnson–Claisen rearrangement of 3-(aryl)cyclohex-2-enols **9b**

Entry <sup>a</sup>	Acid	Triethyl orthoacetate	Solvent	Temp. °C	<sup>b</sup> Yield%
1	10 mol% propanoic acid	10 equiv.	Toluene	130 °C	Mixture of products
2	5 mol% propanoic acid	10 equiv.	Xylene	160 °C	Mixture of products
3	5 mol% pivalic acid	10 equiv.	Xylene	140 °C	Mixture of products
4	5 mol% butyric acid	10 equiv.	Xylene	140 °C	Mixture of products
5	5 mol% <i>o</i> -nitrophenol	10 equiv.	Xylene	160 °C	Mixture of products
6	5 mol% <i>o</i> -nitrophenol	10 equiv.	Xylene	220 °C	62% (68% ee)
7	—	10 equiv.	DIPEA	130 °C	Mixture of products
8	—	10 equiv.	DIPEA	140 °C	20% + 36% (SM)
9	—	10 equiv.	DIPEA	220 °C	73% (97% ee)
10	—	10 equiv.	DIPEA	160 °C	37% + 28% (SM)


<sup>a</sup> All the reactions were performed under argon atmosphere. <sup>b</sup> Yields are reported after column chromatography.




Scheme 5 Proposed reaction mechanism of [3,3]-sigmatropic rearrangement.

generate the key intermediate responsible for [3,3]-sigmatropic rearrangement. Thus, Hünig's base *i.e.* *N,N*-diisopropylethylamine (DIPEA) was used a promoter as well as solvent. It was a pleasure to see that, after exhaustive optimization, 10 equiv. of *N,N*-diisopropylethylamine (DIPEA) and 10 equiv. of triethyl orthoacetate under heating condition produce  $\gamma,\delta$ -unsaturated

ester with 73% yield with 97% enantioselectivity.<sup>24</sup> Interestingly, this reaction afforded enantioenriched [3,3]-sigmatropic rearrangement product (97% ee) with minimum loss of

Scheme 6 Byproduct formation under orthoester Johnson–Claisen rearrangement of (+)-**9b**.




Scheme 7 Proposed DIPEA mediated reaction mechanism of [3,3]-sigmatropic rearrangement.


enantiopurity under elevated temperature in the presence of *N,N*-diisopropylethylamine (DIPEA) (Scheme 7).<sup>25</sup>

Next, the orthoester Johnson–Claisen rearrangement of 2-bromo 3-(aryl)cyclohex-2-enols **12b** was undertaken. Since, 3-(aryl)cyclohex-2-enol having an electron-rich aromatic was difficult, it was thought of exploring the [3,3]-sigmatropic rearrangement of 2-bromo 3-(aryl)cyclohex-2-enol. The reason behind is that the substrate, 2-bromo 3-(aryl)cyclohex-2-enol, has an electron-rich aromatics and at the same time it is having an electron-withdrawing bromo functionality.

Based on this intuition, the orthoester Johnson–Claisen rearrangement was carried out under conventional approach *i.e.* under acid catalyzed process. Gratifyingly, it was observed that orthoester Johnson–Claisen rearrangement of 2-bromo 3-(aryl)cyclohex-2-enol was found to be very efficient and afforded product **8a** in 76% yield (Scheme 8). Pleasingly, this reaction was found to be more facile under microwave condition to afford product in 79% yield (Scheme 8). Next, debromination of bromo group was conveniently done under classical condition with tri-*n*-butyltin hydride in the presence of AIBN. Subsequent direct conversion of **8b** in to the  $\alpha,\beta$ -unsaturated ketone **7b** *via*



Scheme 8 Synthesis of 4-aryl 4-alkyl 2-cyclohexenone (–)-**7b**.



Scheme 9 Ester aminolysis and aza-Michael cascade.

an allylic oxidation ( $\text{CrO}_3$ , 3,5-dimethylpyrazole,  $\text{CH}_2\text{Cl}_2$ ,  $-10^\circ\text{C}$  to  $25^\circ\text{C}$ , 16 h, 77%) set the stage for studies on its cyclization.

4-Aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** in hand, the efforts were put forward for its conversion into the advanced intermediate that is capable for concise total synthesis of *cis*-3a-octahydroindoline alkaloids (Scheme 9). It was hypothesized to synthesize the tricyclic core **1c** from 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** *via* an ester-aminolysis followed by an aza-Michael reaction with methylamine under heating (Scheme 9). Following optimization, it was observed that the treatment of 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** with  $\text{MeNH}_2$  in THF ( $80^\circ\text{C}$ , 16 h) proceeded smoothly furnish bicyclic keto lactam **1c** in 96% yield. A rationale of the formation of keto lactam **1c** from 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** is shown in Scheme 9.


Next, chemoselective reduction of keto carbonyl functionality over carboxamide carbonyl was undertaken. In this regard, a number of reducing agents were selected and reduction was performed under different condition (Table 3). Following extensive optimization using various hydride source such as  $\text{NaBH}_4$ ,  $\text{LiAlH}_4$ , Red-Al, and K-selectride, it was found that a highly stereoselective reduction of ketone group is possible to complete the total synthesis of (–)-2-oxoepimesembranol (**1d**) in excellent yield (99%) and excellent diastereoselectivity ( $>20:1$ )

Table 3 Highly stereoselective reduction of ketone functionality

Entry <sup>a</sup>	Reducing agent	Equivalent	Temp.	Time	Yield <sup>b</sup>	dr
1	$\text{NaBH}_4$ (MeOH)	1 eq.	$0^\circ\text{C}$	1 h	84%	$\sim 8:1$
2	$\text{LiAlH}_4$ (THF)	1 eq.	$0^\circ\text{C}$	1 h	70%	$\sim 5:1$
3	$\text{LiAlH}_4$ (THF)	1 eq.	$-78^\circ\text{C}$	1 h	69%	$\sim 10:1$
4	Red-Al (PhMe)	1 eq.	$25^\circ\text{C}$	4 h	65%	$\sim 5:1$
5	K-selectride (THF)	1 eq.	$-78^\circ\text{C}$	1 h	99%	$>20:1$

<sup>a</sup> All the reactions were performed under argon atmosphere. <sup>b</sup> Yields are reported after column chromatography.






S. No. <sup>a</sup>	oxidizing agent	equivalent	temp.	time	yield <sup>b</sup>
1.	PCC (CH <sub>2</sub> Cl <sub>2</sub> )	1.5 eq.	0 °C	1 h	40%
2.	swern (CH <sub>2</sub> Cl <sub>2</sub> )		0 °C	1 h	58%
3.	DMP (DMSO)	1.2 eq.	0 °C	1 h	80%
4.	IBX (DMSO)	1.5 eq.	25 °C	3 h	83%

**Scheme 10** Collective total synthesis of *cis*-3a-octahydroindoline alkaloids. <sup>a</sup>All the reactions were performed under argon atmosphere. <sup>b</sup>Yields are reported after column chromatography.


(Table 3). Thus, a two-step total synthesis of *cis*-3a-octahydroindoline alkaloid, (–)-2-oxoepimesembranol (**1d**) was accomplished from 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** via an ester-aminolysis followed by an aza-Michael reaction and subsequent chemoselective reduction of keto carbonyl functionality over carboxamide carbonyl.

Next, the reductive removal of the lactam carbonyl of **1d** upon treatment with LiAlH<sub>4</sub> (5 equiv, THF, 70 °C reflux, 6 h) completed the total synthesis of (–)-6-epimesembranol (**1b**) in 92% yield (Scheme 10). Further, the treatment with IBX in DMSO (25 °C, 3 h) affords the (–)-mesembrine (**1a**) in 83% yield (Scheme 10). It is understood that, further utilization of this intermediate in the collective total synthesis of *cis*-3a-octahydroindoline alkaloid could be easily achieved with any kind of electron-rich aromatic ring present in these alkaloids. As both enantiomers [*R*] as well as [*S*] of CBS catalyst is commercially available, one could synthesize both antipode of the natural product only by changing the enantiomers of catalyst.

Next the total synthesis of naturally occurring dihydromaritidine was undertaken. Towards this end, it was hypothesized to synthesize the tricyclic core **6b** from 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** via an ester-aminolysis followed by an aza-Michael reaction with ammonia under heating. Following optimization, it was observed that the treatment of 4-aryl 4-alkyl  $\alpha,\beta$ -unsaturated ketone **7b** with NH<sub>3</sub> in THF (70 °C, 16 h) proceeded smoothly furnish bicyclic keto lactam **6b** in 94% yield (Scheme 11). Further, keto functional group of the bicyclic keto lactam **6b** was protected with ethylene glycol in the presence of catalytic amount *p*-toluene sulfonic acid to afford **13b** in 98% yield (Scheme 12). Later, lithium aluminium hydride reduction in tetrahydrofuran under reflux afforded *cis*-8a-octahydroindole derivative **14b** in 94% yield. Other reducing agents such as Red-Al, superhydride were proved to be inefficient for this transformation. The work-up process of reduction of **13b**



**Scheme 11** Ester aminolysis with ammonia and aza-Michael cascade.




**Scheme 12** Synthesis of *cis*-3a-octahydroindoline skeleton.

(particularly the quench of lithium aluminum hydride) is worth mentioning, which was done under the basic condition using 1(N) NaOH. It was observed that an acidic work up using 0.5(N) HCl always afforded a mixture of spots, probably because of the deprotection of ketal functional group.


With significant quantity of *cis*-C-8a-octahydroindole derivative **14b** in hand, the next effort was put forward to affect the Pictet–Spengler cyclization to obtain [5,11*b*]-ethanophenanthridine skeleton (Scheme 13). In this regard, a number of formaldehyde equivalents such as para-formaldehyde, 1,3,5-trioxane, Eschenmoser salt, and formalin were used. Following an exhaustive optimization (Table 4), it was delighted to observe that the synthesis of required [5,11*b*]-ethanophenanthridine skeleton, *i.e.* (+)-dihydrooxomaritidine (**15b**) could be obtained in 91% from a reaction of **14b** and formalin (aqueous solution) in methanol in the presence of 6(N) HCl.

A rational of the formation of Pictet–Spengler cyclization product *i.e.* the total synthesis of (+)-dihydrooxomaritidine (**15b**)



**Scheme 13** Proposed mechanism for the synthesis of [5,10*b*]-ethanophenanthridine skeleton.




Table 4 Pictet–Spengler cyclization of compound **14b**


S. no. <sup>a</sup>	Acid	HCHO equivalent	Temp.	Time	Yield <sup>b</sup>
1	TFA	Paraformaldehyde	0 °C	8 h	62%
2	TFA	1,3,5-Trioxane, BF <sub>3</sub> ·OEt <sub>2</sub>	0 °C	8 h	56%
3	None	Eschenmoser salt	40 °C	3 h	65%
4	TFA	Formalin	0 °C	24 h	71%
5	6(N)	Formalin	40 °C	3 h	91%

<sup>a</sup> All the reactions were performed under argon atmosphere. <sup>b</sup> Yields are reported after column chromatography.

Table 5 Highly stereoselective reduction of ketone functionality



S. no. <sup>a</sup>	Reducing agent	Equivalent	Temp.	Time	Yield <sup>b</sup>	dr
1	NaBH <sub>4</sub> (MeOH)	1 eq.	−10 °C	1 h	98%	~10 : 1
2	LiAlH <sub>4</sub> (THF)	1 eq.	0 °C	1 h	90%	~5 : 1
3	LiAlH <sub>4</sub> (THF)	1 eq.	−10 °C	5 h	69%	~10 : 1
4	Red-Al (PhMe)	1 eq.	25 °C	4 h	65%	~10 : 1
5	K-selectride (THF)	1 eq.	−78 °C	1 h	99%	>20 : 1

<sup>a</sup> All the reactions were performed under argon atmosphere. <sup>b</sup> Yields are reported after column chromatography.

from *cis*-3*a*-octahydroindole derivative **14b** is shown in Scheme 13. An initial deprotection of ketal functionality in the presence of 6(N) HCl could afford ketone **14c**, which on subsequent reaction with formalin could generate a hemi-aminal **22a** (Scheme 13). Further activation of the hemi-aminal **22a** in the presence of HCl could form iminium intermediate **22b**, thereby the stage is ready for the Pictet–Spengler cyclization. Finally, the formation of [5,11*b*]-ethanophenanthridine skeleton, *i.e.* (+)-dihydrooxomaritidine (**15b**) would complete *via* an aromatic electrophilic substitution type reaction (Scheme 13).

The next effort was to synthesize the naturally occurring *Amaryllidaceae* alkaloids, (+)-dihydromaritidine (**2c**) sharing [5,11*b*]-ethanophenanthridine skeleton. In this regard a highly diastereoselective reduction of ketone was undertaken (Table 5). Towards this, number of reducing agents such as sodium borohydride, lithium aluminum hydride, Red-Al, and K-selectride, were employed for the total synthesis of

(+)-dihydromaritidine (**2c**). Among various reducing agent, K-selectride was found to be the best and furnished the natural product **2c** in 99% yield with >20 : 1 diastereoselectivity (entry 5, Table 5). Gratifyingly, a reduction using sodium borohydride at −10 °C afforded the required (+)-dihydromaritidine (**2c**) in 98% yield with 10 : 1 dr (entry 1, Table 5).

In conclusion, we describe a general approach to a number of alkaloids of *Sceletium* alkaloids of the family *Aizoaceae* following Johnson (orthoester)–Claisen rearrangement as the key step. It has been shown that acid catalysed process afforded product with compromised enantioselectivity, whereas a reaction in basic medium (such as diisopropylethylamine, DIPEA) could afford [3,3]-sigmatropic rearrangement product<sup>26</sup> in 97% ee. Importantly, this reaction installed all carbon quaternary stereocenter at the pseudobenzyl position. The enantioenriched 3-(aryl)cyclohex-2-enol and 2-bromo 3-(aryl)cyclohex-2-enol were prepared by using catalytic enantioselective CBS reduction (up to 99% ee). Utilizing aforementioned strategy, a collective total synthesis of (−)-2-oxo-epimesembranol (**1d**), (−)-6-epimesembranol (**1b**), and (−)-mesembrine (**1a**) were shown. Further utilizing **7b** *via* an ester aminolysis with ammonia followed by Pictet–Spengler cyclization leads to completion the total synthesis of (+)-dihydrooxomaritidine (**15b**) and (+)-dihydromaritidine (**2c**).

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

Financial support from the SERB [CRG/2023/000782], [SCP/2022/000486], CSIR [02(0403)/21/EMR-II] and partial support from STARS-MoE [2023/0753] is gratefully acknowledged. SM thanks the CSIR for a research fellowship (SRF). AY and SP thank IISERB for fellowships (JRFs). AM thanks the UGC for fellowship. AB is a SERB-STAR Fellow and sincerely acknowledges the SERB [STR/2020/000061] for generous support.

## Notes and references

- (a) G. N. Trinadhachari, A. G. Kamat, K. R. Babu, P. D. Sanasi and K. J. Prabahar, *Tetrahedron: Asymmetry*, 2014, **25**, 117–124; (b) H. Kimura, T. Kawai, Y. Hamashima, H. Kawashima, K. Miura, Y. Nakaya, M. Hirasawa, K. Arimitsu, T. Kajimoto, Y. Ohmomo, M. Ono, M. Node and H. Saji, *Bioorg. Med. Chem.*, 2014, **22**, 285–291; (c) T. Ozaki and Y. Kobayashi, *Org. Chem. Front.*, 2015, **2**, 328–335; (d) K. Geoghegan and P. Evans, *J. Org. Chem.*, 2013, **78**, 3410–3415.
- (a) P. Lan, C. J. Jackson, M. G. Banwell and A. C. Willis, *J. Org. Chem.*, 2014, **79**, 6759–6764; (b) J. McNulty and C. Zepeda-Velazquez, *Angew. Chem., Int. Ed.*, 2014, **53**, 8450–8454.
- (a) N. Cortes, R. A. Posada-Duque, R. Alvarez, F. Alzate, S. Berkov, G. P. Cardona-Gomez and E. Osorio, *Life Sci.*, 2015, **122**, 42–50; (b) W. Poet, D. Tagwireyi, H. M. Chinyanga, C. Musara, G. Nyandro, J. Chifamba and





- P. Nkomozezi, *J. Ethnopharmacol.*, 2013, **148**, 379–385; (c) V. Georgiev, I. Ivanov, S. Berkov and A. Pavlov, *J. Plant Biochem. Biotechnol.*, 2014, **23**, 389–398.
- 4 (a) J. J. Nair, J. Bastida, C. Codina, F. Viladomat and J. V. Staden, *Nat. Prod. Commun.*, 2013, **8**, 1335; (b) Z. Jin and X.-H. Xu, in *Natural Products: Phytochemistry, Botany and Metabolism of Alkaloids, Phenolics and Terpenes*, ed. K. G. Ramawat and J. M. Merillon, Springer-Verlag, Berlin Heidelberg, 2013, p. 497; (c) Y. Ding, D. Qu, K.-M. Zhang, X.-X. Cang, Z.-N. Kou, W. Xiao and J.-B. Zhu, *J. Asian Nat. Prod. Res.*, 2016, **12**, 1.
- 5 Reviews on *Amaryllidaceae* alkaloids, see: (a) Z. Jin, *Nat. Prod. Rep.*, 2009, **26**, 363; (b) J. R. Lewis, *Nat. Prod. Rep.*, 2002, **19**, 223; (c) Z. Jin, Z. Li and R. Huang, *Nat. Prod. Rep.*, 2002, **19**, 454.
- 6 The effects of *Sceletium tortuosum* in an *in vivo* model of psychological stress. M. T. Smith, N. R. Crouch, N. Gericke and M. Hrisht, *J. Ethnopharmacol.*, 1996, **133**, 119–130.
- 7 (a) Pharmacological actions of the South African medicinal and functional food plant *Sceletium tortuosum* and its principal alkaloids. A. L. Harvey, L. C. Young, A. M. Viljoen and N. P. Gericke, *J. Ethnopharmacol.*, 2011, **137**, 1124–1129; (b) R. E. Schultes, *Hallucinogenic Plants*, Golden Press, New York, 1976; (c) P. W. Jeffs, in *The Alkaloids*, ed. Rodrigo, R. G. A., Academic Press, New York, 1981, vol. 19.
- 8 Assessing African medicinal plants for efficacy and safety: agricultural and storage practices. C. W. Fennell, M. E. Light, S. G. Sparg, G. I. Stafford and J. Van Staden, *J. Ethnopharmacol.*, 2004, **95**, 113–121.
- 9 K. Bodendorf and W. Krieger, *Arch. Pharm.*, 1957, **290**, 441–448.
- 10 For representative racemic syntheses, see: (a) G. E. Keck and R. R. Webb II, *J. Am. Chem. Soc.*, 1981, **103**, 3173; (b) I. H. Sánchez, F. J. López, J. J. Soria, M. I. Larraza and H. J. Flores, *J. Am. Chem. Soc.*, 1983, **105**, 7640; (c) C. Bru, C. Thal and C. Guillou, *Org. Lett.*, 2003, **5**, 1845; (d) N. T. Tam and C.-G. Cho, *Org. Lett.*, 2008, **10**, 601; (e) G. Pandey, N. R. Gupta and T. M. Pimpalpal, *Org. Lett.*, 2009, **11**, 2547; (f) K. M. Bogle, D. J. Hirst and D. J. Dixon, *Org. Lett.*, 2010, **12**, 1252; (g) D. A. Candito, D. Dobrovolsky and M. Lautens, *J. Am. Chem. Soc.*, 2012, **134**, 15572; (h) M. K. Das, S. De, Shubhashish and A. Bisai, *Synthesis*, 2016, **48**, 2093; (i) S. Raghavan and A. Ravi, *Org. Biomol. Chem.*, 2016, **14**, 10222; (j) N. Gao, M. Banwell and A. C. Willis, *Org. Lett.*, 2017, **19**, 162.
- 11 (a) S. Akai, M. Kojima, S. Yamauchi, T. Kohji, Y. Nakamura and K. Sato, *Asian J. Org. Chem.*, 2013, **2**, 299–302; (b) S. P. Chavan, S. Garai, C. Dey and R. G. Gonnade, *Tetrahedron Lett.*, 2013, **54**, 5562–5566.
- 12 (a) F. Sandberg and K.-H. Michel, *Lloydia*, 1963, **26**, 78; (b) R. V. K. Rao and J. V. L. N. Sheshagiri Rao, *Curr. Sci.*, 1979, **48**, 110; (c) P. Pacheco, M. Silva, W. Steglich and W. H. Watson, *Rev. Latinoam. Quim.*, 1978, **9**, 28; (d) S. Toaima and M. Alexandria, *J. Pharm. Sci.*, 2007, **21**, 61; (e) V. Zabel, W. H. Watson, P. Pacheco and M. Silva, *Cryst. Struct. Commun.*, 1979, **8**, 371.
- 13 For biological activity of maritidine, see: (a) N. P. Gericke, and B. E. Van Wyk, WO97/46234, 1997, Chem. Abstr., 1998, 12880030, (serotonin uptake inhibitor); (b) E. E. Elgorashi, G. I. Stafford, A. K. Jager and J. van Staden, *Planta Med.*, 2006, **72**, 470–473 (inhibition of [ $^3H$ ]citalopram binding to the rat brain serotonin transporter); (c) G. Cea, M. Alarcon and G. Weigart, *Med. Sci.*, 1986, **14**, 90 (clastogenic effect/mutagenic).
- 14 (a) M. Alarcon, G. Cea and G. Weigert, *Environ. Contam. Toxicol.*, 1986, **37**, 508; (b) G. Cea, M. Alarcon and G. Weigart, *Med. Sci.*, 1986, **14**, 90 (clastogenic effect/mutagenic).
- 15 For the total synthesis of (–)-oxomaritidine or (+)-maritidine by using a diastereoselective desymmetrization, see: (a) K. Tomioka, K. Koga and S. Yamada, *Chem. Pharm. Bull.*, 1977, **25**, 2681; (b) P. Verma, A. Chandra and G. Pandey, *J. Org. Chem.*, 2018, **83**, 9968; (c) For an elegant resolution of racemic oxomaritidine to (–)-oxomaritidine by Ir-catalyzed asymmetric hydrogenation, see: X.-D. Zuo, S.-M. Guo, R. Yang, J.-H. Xie and Q.-L. Zhou, *Chem. Sci.*, 2017, **8**, 6202.
- 16 For representative asymmetric syntheses, see: (a) T. Nishimata, Y. Sato and M. Mori, *J. Org. Chem.*, 2004, **69**, 1837; (b) K. Du, H. Yang, P. Guo, L. Feng, G. Xu, Q. Zhou, L. W. Chung and W. Tang, *Chem. Sci.*, 2017, **8**, 6247; (c) Y. R. Gao, D.-Y. Wang and Y.-Q. Wang, *Org. Lett.*, 2017, **19**, 3516; (d) A. Yadav, S. Majumder, M. K. Das, A. Mondal and A. Bisai, *Synlett*, 2023, **34**, 858.
- 17 Chiral-pool strategy from carbohydrates, see: (a) S. W. Baldwin and J. S. Debenham, *Org. Lett.*, 2000, **2**, 99; (b) M. Bohno, H. Imase and N. Chida, *Chem. Commun.*, 2004, 1086; (c) A. D. Findlay and M. G. Banwell, *Org. Lett.*, 2009, **11**, 3160 (chemoenzymatic resolution).
- 18 (a) R. E. Lyle, E. A. Kielar, J. R. Crowder and W. C. Wildman, *J. Am. Chem. Soc.*, 1960, **82**, 2625; (b) F. Viladomat, J. Bastida, C. Codina, W. E. Campbell and S. Mathee, *Phytochemistry*, 1995, **40**, 307.
- 19 (a) B. M. Trost, G. M. Schroeder and J. Kristensen, *Angew. Chem., Int. Ed.*, 2002, **41**, 3492; (b) B. M. Trost, J. Xu and T. Schmidt, *J. Am. Chem. Soc.*, 2009, **131**, 18343.
- 20 (a) J. Park, Y. K. Kim, G. Kim and B. Korean, *Chem. Soc.*, 2011, **32**, 3141; (b) M. K. Das, N. Kumar and A. Bisai, *Org. Lett.*, 2018, **20**, 4421–4424; (c) W. Wang, J. Dai, Q. Yang, Y.-H. Deng, F. Peng and Z. Sao, *Org. Lett.*, 2021, **23**, 920–924.
- 21 H. Kim, H. Choi and K. Lee, *Synlett*, 2018, **29**, 1203–1206.
- 22 (a) E. J. Corey and G. W. J. Fleet, *Tetrahedron Lett.*, 1973, **14**, 4499; (b) For CBS reduction of 2-aryl-2-cyclohexenone, see: S. Khatua, S. Niyogi and V. Bisai, *Tetrahedron*, 2020, **76**, 130918; (c) A similar type of transition state has been proposed.
- 23 (a) S. Hackett and T. Livinghouse, *J. Org. Chem.*, 1986, **51**, 1629; (b) O. Yamada and K. Ogasawara, *Tetrahedron Lett.*, 1998, **39**, 7747.
- 24 E. J. Corey and C. J. Helal, *Angew. Chem., Int. Ed.*, 1998, **37**, 1986–2012.
- 25 S. Majumder, A. Yadav, S. Pal, A. Khatua and A. Bisai, *J. Org. Chem.*, 2022, **87**, 7786–7797.
- 26 V. R. Gavit, S. Kundu, S. Niyogi, N. K. Roy and A. Bisai, *J. Org. Chem.*, 2024, **89**, 1823–1835.

